

## Studies on the in vitro and in vivo antiurolithic activity of *Holarrhena antidysenterica*

Aslam Khan · Saeed R. Khan · Anwar H. Gilani

Received: 3 February 2012 / Accepted: 2 May 2012 / Published online: 24 May 2012  
© Springer-Verlag 2012

**Abstract** *Holarrhena antidysenterica* has a traditional use in the treatment of urolithiasis, therefore, its crude extract has been investigated for possible antiurolithic effect. The crude aqueous-methanolic extract of *Holarrhena antidysenterica* (Ha.Cr) was studied using the in vitro and in vivo methods. In the in vitro experiments, Ha.Cr demonstrated a concentration-dependent (0.25–4 mg/ml) inhibitory effect on the slope of aggregation. It decreased the size of crystals and transformed the calcium oxalate monohydrate (COM) to calcium oxalate dehydrate (COD) crystals, in calcium oxalate metastable solutions. It also showed concentration-dependent antioxidant effect against 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radicals and lipid peroxidation induced in rat kidney tissue homogenate. Ha.Cr (0.3 mg/ml) reduced ( $p < 0.05$ ) the cell toxicity and LDH release in renal epithelial cells (MDCK) exposed to oxalate (0.5 mM) and COM (66  $\mu\text{g}/\text{cm}^2$ ) crystals. In male Wistar rats, receiving 0.75 % ethylene glycol (EG) for 21 days along with 1 % ammonium chloride (AC) in drinking water, Ha.Cr treatment (30–100 mg/kg) prevented the toxic changes caused by lithogenic agents; EG and AC, like loss of body weight,

polyurea, oxaluria, raised serum urea and creatinine levels and crystal deposition in kidneys compared to their respective controls. These data indicate that *Holarrhena antidysenterica* possesses antiurolithic activity, possibly mediated through the inhibition of CaOx crystal aggregation, antioxidant and renal epithelial cell protective activities and may provide base for designing future studies to establish its efficacy and safety for clinical use.

**Keywords** Urolithiasis · *Holarrhena antidysenterica* · In vitro · In vivo · MDCK cell line · Rats

### Introduction

Urolithiasis, urinary stone formation, is the third most common problem of the urinary tract, sparing no geographical, racial and cultural boundaries and is associated with high rate of recurrence [1, 2]. In Pakistan its prevalence is 10–15 %, while its complication can lead to acute or chronic renal failure, pyelonephritis, pyonephritis and perinephric abscess, which can present with life threatening situations and even death [3].

Despite the fact that the currently available stone removal techniques like extracorporeal shock wave lithotripsy (ESWL), ureteroscopy (URS), and percutaneous nephrolithotomy (PNL), are considered to be effective, but they are costly, making them an option of choice for limited number of patients and a compelling data suggest that these techniques have some serious side effects [4]. Moreover, the high rate of recurrence in stone formation, which is around 50 % at a 5-year follow-up [3], makes it a chronic condition which underscores the importance of preventive therapy [5]. In spite of substantial progress in the study of the biological and physical manifestation of urolithiasis, its mechanism is still

A. Khan  
Department of Pharmacology, Faculty of Pharmacy,  
University of Karachi, Karachi, Pakistan  
e-mail: aslamkhan\_mkd@yahoo.co.uk

A. Khan · A. H. Gilani (✉)  
Natural Product Research Division, Department of Biological  
and Biomedical Sciences, Aga Khan University Medical  
College, Karachi 74800, Pakistan  
e-mail: anwar.gilani@aku.edu

S. R. Khan  
Centre for the Study of Lithiasis, Department of Pathology,  
College of Medicine, University of Florida, Gainesville, USA  
e-mail: khan@pathology.ulf.edu

not clearly understood [6] and there is no satisfactory drug available for the treatment of urolithiasis, especially for the prevention of recurrence of the stones [7]. The agents used clinically for prophylactic therapy are primarily aimed to correct the underlying metabolic disorders, but the evidence for their effectiveness is still not convincing in addition to their side effects and tolerability [8, 9]. One reason for a limited success of chemical drugs in urolithiasis is that multiple factors are involved in its pathogenesis [10] and thus treatment demands multiple targets, such as antispasmodic, antioxidant, anti-inflammatory activities [11]. The medicinal plants that are known to contain multiple chemical constituents, which could offer a synergistic and/or side-effect neutralizing combinations [12], are likely to offer more effective and safer remedy particularly in urolithiasis. Therefore, there is a need to look for an alternative therapy, especially herbal remedies, for the management and treatment of urolithiasis, which have the potential to be effective in urolithiasis [13]. In addition, herbal medicines are considered to be relatively safer, economical and accessible to large population of the developing countries like Pakistan [12]. Therefore, we evaluated the seeds of *Holarrhena antidysenterica* Wall (Apocynaceae) for its antiurolithic activity because of its traditional use as a lithotriptic, along with other uses like colic, diarrhea, dysentery, constipation, flatulence, carminative, antispasmodic, astringent, diuretic and antihypertensive [14, 15].

*Holarrhena antidysenterica* is known to contain conesine, ergosterol, holarrhenine, kurchicine, resin and tannin [16, 17] and has been reported to possess antimutagenic [18], antibacterial [19], immuno-modulatory [20], antispasmodic [21] and diuretic [22] properties.

This study has been undertaken to investigate the antiurolithic activity of the seeds of *Holarrhena antidysenterica* using Ethylene glycol-induced rat model of CaOx urolithiasis and the in vitro assays to investigate its calcium oxalate crystallization inhibitory, antioxidant, renal cell protective and antispasmodic activities.

## Materials and methods

### Chemicals and reagents

The following chemicals were obtained from the Merck, Darmstadt, Germany, BDH Laboratory supplies, Poole, England and Sigma Chemical Company, St. Louis, MO, USA. Kits used in this study for the determination of calcium, magnesium, and blood urea nitrogen (BUN) were supplied by Randox Laboratories Ltd. Ardmore, Diamond Road, Crumlin, Co. Antrim, UK. Oxalate estimation was done by the kit from Trinity Biotech Plc, IDA business park, Bray, Co. Wicklow. All the chemicals used were of analytical grade available.

### Animals

Experiments were performed in compliance with the rulings of the Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council (1996) [23] and approved by the Ethical Committee for Research on Animals (ECRA) of the Aga Khan University, Karachi, Pakistan.

### Plant material and extraction

Dried seeds of *Holarrhena antidysenterica* were taken from local herbal store, identified by a taxonomist, Prof. Dr. Jhandar Shah, University of Malakand, Chakdara, Khyber Pakhtunkhwa, Pakistan and voucher specimen (HA-SE-01-08-71) was submitted to the herbarium of the Department of Biological and Biomedical Sciences, the Aga Khan University, Karachi. The clean seeds were extracted with 70 % aqueous-ethanol and kept for 3 days with occasional shaking. It was filtered through a muslin cloth and then through a Whatman qualitative grade 1 filter paper. This procedure was repeated twice and the combined filtrate was evaporated on rotary evaporator under reduced pressure (–60mmHg) to a thick, semi-solid mass of brown color, i.e. the crude extract of *Holarrhena antidysenterica* seeds (Ha.Cr), yielding ~18 % w/w [24].

### In vitro experiments

#### Determination of CaOx crystallization

The effect of the Ha.Cr on kinetics of calcium oxalate (CaOx) crystallization was determined by the time course measurement of turbidity changes due to the crystal nucleation and aggregation after mixing metastable solutions of calcium ( $\text{Ca}^{++}$ ) and oxalate (Ox). While the effect on the number, size and morphology of the crystals was determined by incubating different concentrations of Ha.Cr with the metastable solutions of  $\text{Ca}^{++}$  and Ox as described previously [25].

#### Determination of antioxidant activity

Antioxidant potential of the Ha.Cr was estimated by its effect on free radical scavenging activity [26] and its inhibitory effect against lipid peroxidation induced in rat kidney homogenate with ferrous-ascorbate system, as described previously [27].

#### Cell lines (MDCK) experiment

Madin Darby canine kidney (MDCK) cells, obtained from ATCC (Cat.# CRL-34; Manassa, VA, U.S.A), were

maintained as sub-confluent monolayers at 37 °C in 5 % CO<sub>2</sub>. The culture was grown and maintained in 75 cm<sup>2</sup> Falcon tissue culture flasks as discussed previously.

#### *Determination of cell viability and LDH release*

After incubating the cells for 24 h with Ox (0.5 mM) or COM crystals (67 µg/cm<sup>2</sup>), renal cells toxicity was determined by XTT cell viability Assay Kit (Biotium, Inc., Hayward, Ca, USA Cat # 30007), while LDH release was estimated by CytoTox 96 Non-Radioactive Cytotoxicity assay kit (Fisher Scientific, Norcross, GA, Promega Cat # PR-G1780).

#### *In vivo experiments*

##### *Study on animal model of urolithiasis*

Antiurolithic activity of the test material was determined using hyperoxaluric rat model of CaOx urolithiasis described previously [11, 28, 29]. Male Wistar rats (weighing 180–220 g) were divided with matched body weights into groups of 6–8 animals each, which were then randomly selected to receive various treatments. In this study, rats were divided into five groups. Group I serving as normal control, received intraperitoneal (i.p.) injections of normal saline (2.5 ml/kg), once in 24 h. Group II serving as the Ha.Cr control received only the Ha.Cr (100 mg/kg), Group III serving as the lithogenic control received stone inducing treatment, while group IV and V received the lithogenic treatment along with the Ha.Cr 30 and 100 mg/kg, respectively. Lithogenic treatment was given for 21 days and comprised of 0.75 % (w/v) ethylene glycol (EG) with 1 % (w/v) ammonium chloride (AC) in drinking water for 5 days, following this the water supply was switched to 0.75 % EG alone in water [28, 30], along with saline treatment. Animal weight and activity were regularly monitored to assess their overall health. 24 h urine samples were collected immediately before the onset and at the end of total 21 days of treatment, for which animals were housed individually in metabolic and diuretic cages. The 3 h morning urine for crystalluria study was also collected at the end of 21 days of treatments. The number of the crystals/mm<sup>3</sup> was counted under light microscope using hemocytometer.

Following volume and pH determination, part of each 24-h urine sample was acidified to pH 2 with 5 M HCl. Both acidified and non-acidified urine samples were then centrifuged at 1,500g for 10 min to remove debris and supernatants were stored at –20 °C until analyzed. Blood was collected through cardiac puncture from animals under ether anesthesia for serum separation to assess serum creatinine and BUN. Animals were sacrificed and both the kidneys were excised, rinsed in ice cold physiological

saline and weighed. The right kidney was fixed in 10 % neutral buffered formalin, processed, embedded in paraffin wax, sectioned at 5 µm and stained with hematoxylin and eosin (H & E) and by Pizzolato's method, for calcium oxalate crystals [31], for microscopic examination.

#### *Calcium oxalate crystal deposition in kidney*

Crystal distribution within the kidneys was determined using the semiquantitative scoring by the methods used previously [11, 32]. Briefly, the crystal deposits in stained sections with visible in a field of 10× magnification were counted and severity grades were assigned as 0 = <1 crystals, 1 = ≤1–10, 2 = ≤11–30, 3 = ≤31–50, 4 = ≤51–75 and 5 = >75 crystals. Most of the crystals were located in the outer modularly and cortical region of the kidney.

#### *Biochemical analysis of urine and serum*

In acidified urine samples, Ox, Ca<sup>++</sup> and Mg<sup>++</sup> contents were determined using commercially available kits. Inorganic phosphate (PO<sub>4</sub><sup>2-</sup>) excretion was determined by the molybdenum blue reaction [33]. In non-acidified urine samples, citrate, creatinine and uric acid (UA), while in serum, creatinine and BUN were estimated with the help of kit-based methods. Total protein in non-acidified urine was estimated by lowery method [34] based on the development of blue color as a result of a combination of two reaction involving the interaction Cu<sup>2+</sup> in the presence of base with peptide bonds and Folin–Ciocalteu phenol reagent with tyrosine and tryptophan residues.

#### *Data analysis*

The data expressed are mean ± standard error of mean (SEM) and the median effective concentration (EC50 value) with 95 % confidence intervals (CI). All statistical comparisons between the groups are made by means of *t* test (comparison between two groups) or one way analysis of variance (ANOVA) with post hoc Dunnett's test using GraphPad Prism (GraphPad Software, San Diego, CA, USA). *p* value <0.05 is regarded as significant.

## **Results**

### *In vitro experiment*

#### *Effect on in vitro crystallization*

Effect of Ha.Cr on various phases of CaOx crystallization was determined by time course measurement of turbidity under standard conditions (4.25 mM Ca<sup>++</sup> and 0.75 mM Ox).

Typical tracings of the experiment in the presence of Ha.Cr and potassium citrate are shown in Fig. 1a, b. Ha.Cr inhibited the  $S_A$  with an  $IC_{50}$  of 0.27 mg/ml (95 % CI 0.23–0.33), similar to potassium citrate, which caused dose-dependent inhibition with  $IC_{50}$  value of 0.31 mM (95 % CI 0.30–0.52) as shown in Fig. 1c. Ha.Cr did not significantly decrease the slopes of nucleation (1–4 mg/ml), while potassium citrate caused  $31 \pm 2.31$ ,  $42 \pm 4.0$ ,  $65 \pm 4.2$  and  $85 \pm 5.2$  % inhibition at a concentration of 0.5, 1, 2 and 4 mM, respectively (Fig. 1d). In the incubation study, mixing the metastable solutions of  $Ca^{++}$  and Ox resulted in the formation of CaOx crystals predominately of COM (Fig. 2a). Ha.Cr did not influence the number of crystal formation, but significantly decreased the size and morphology of the crystals from COM to COD (Fig. 2b), whereas potassium citrate reduced the number as well as the size and morphology of the crystals from COM to COD (Fig. 2c).

### Antioxidant effect


Ha.Cr caused inhibition of DPPH free radical with  $IC_{50}$  value of 14.4  $\mu$ g/ml (95 % CI 11.21–18.35), while the


control drug BHT inhibited DPPH with  $IC_{50}$  value of 3.42  $\mu$ g/ml (95 % CI 3.166–3.692) as shown in Fig. 3a. Ha.Cr inhibited lipid peroxidation, induced in rat kidney homogenate by  $13.40 \pm 3.40$  and  $42.40 \pm 3.10$ , while BHT caused  $30.85 \pm 2.60$  and  $71.60 \pm 3.84$  % inhibition of lipid peroxidation at 50 and 150  $\mu$ g/ml, respectively (Fig. 3b).

### Effect on kidney epithelial cell lines (MDCK)

Ha.Cr had no toxic effect on MDCK cells up to 0.3 mg/kg. However, it reduced significantly the cell viability at a concentration of 1 mg/ml or more (Fig. 4a). The cell viability was decreased significantly ( $p < 0.001$ ) in the untreated control after exposure to 0.5 mM Ox or 66  $\mu$ g/cm<sup>2</sup> of COM. However, the treatment of Ha.Cr significantly ( $p < 0.05$ ) increased the cell viability at a concentration of 0.3 mg/ml compared to untreated control (Fig. 4b, c). LDH release was significantly increased after exposure to 0.5 mM oxalate or 66  $\mu$ g/cm<sup>2</sup> COM versus untreated control. However, after pretreatment with Ha.Cr, the LDH decreased was significantly at the concentration of 0.3 mg/ml (Fig. 4d, e).

**Fig. 1** Calcium oxalate crystallization study. Effect of *Holarrhena antidysenterica* (Ha.Cr) and Potassium Citrate (K-Cit) on calcium oxalate crystallization. **a, b** Typical tracing of the control in the presence of Ha.Cr and potassium citrate. **c** The concentration response curves of *Holarrhena antidysenterica* and potassium citrate on  $S_A$  of the turbidity curves, **d** the % inhibition on the  $S_N$ . Symbols shown are mean  $\pm$  SEM ( $n = 3$ ).  $S_N$  and  $S_A$  represent slope of nucleation and slope of aggregation, respectively






**Fig. 2** Calcium oxalate incubation study. Representative photographs, under inverted microscope (200 $\times$ ), of CaOx crystals developed in the metastable solutions in the absence (a) and in the presence of *Holarrhena antidysenterica* (Ha.Cr) 2 mg/ml (b) and 2 mM K-citrate (c)

### In vivo experiments

In the in vivo study, all the parameters, like body weights, 24 h water intake, urine volume, urinary pH and composition, recorded before the treatment were not significantly different among the groups. The parameters recorded at day 0 and at the end of 3 weeks of treatment period are listed in the Table 1.

Ha.Cr had no significant effect on the CaOx crystalluria, however, the crystals (mostly CaOx dehydrate) found in




**Fig. 3** Antioxidant activity. Concentration response curves of the free radical scavenging activity of the butylated hydroxytoluene (BHT) and *Holarrhena antidysenterica* (Ha.Cr), while bar chart (b) representing lipid peroxidation inhibitory activity of two different concentrations of Ha.Cr and BHT. Inhibition is measure as % of the respective control experiments. The values shown are mean  $\pm$  SEM ( $n = 3$ )

the treated groups were quite smaller than those found in the untreated lithogenic group (Fig. 5). The body weight was significantly ( $p < 0.01$  vs. normal) reduced in stone forming group as compared to the normal saline group. The co-administration of Ha.Cr (30–100 mg/ml) prevented ( $p < 0.05$  vs. stone forming group) the loss in body weight. The 24-h urine volume and water intake were higher ( $p < 0.01$ ) in the stone forming group compared to that in the normal saline animals. Urine pH was slightly reduced in the stone forming group, though not to a significant extent. A co-treatment with Ha.Cr significantly reduced ( $p < 0.05$ ) polyurea and water intake compared to stone forming group. Similarly, oxalate excretion was significantly increased ( $p < 0.01$ ) in stone forming animals, whereas  $\text{Ca}^{++}$  excretion was decreased ( $p < 0.05$ ). Urine

**Fig. 4** Effect on MDCK cells. Effects of various concentrations of Ha.Cr on MDCK cell survival in acclimatization media (a). b, c The protective effect of Ha.Cr after exposure to 0.5 mM oxalate or 66  $\mu\text{g}/\text{cm}^2$  COM, respectively. d, e The percent increase in LDH release against control by MDCK cells exposed Ox. (0.5 mM) and COM (66  $\mu\text{g}/\text{cm}^2$ ) for 24 h. Data shown are mean  $\pm$  SEM of two separate experiments with three independent replicates.

\* $p < 0.05$ , \*\* $p < 0.05$  and \*\*\* $p < 0.001$



contents of citrate, phosphate, uric acid (UA),  $\text{Mg}^{2+}$ ,  $\text{Na}^+$  and  $\text{K}^+$  were not altered to a significant level ( $p > 0.05$ ). Co-administration of Ha.Cr (30–100 mg/kg) to EG treatment group significantly ( $p < 0.05$ ) decreased oxalate excretion, whereas unlike control group,  $\text{Ca}^{2+}$  excretion remained unchanged in the treated groups as compared to the normal group. EG treatment caused impairment of renal functions of the untreated rats as evident from total protein loss and raised BUN and serum creatinine

( $p < 0.05$ ), which were prevented in the animals treated with Ha.Cr (Table 1).

In the histological preparations of kidneys, the normal saline group did not show any crystalline deposits. Whereas, a high score of crystal deposits were observed under polarized light in all regions of kidneys in lithogenic group. However, in Ha.Cr treated groups, significantly less number of CaOx crystal deposits ( $p < 0.05$ ) were observed as compared to untreated EG (lithogenic) group (Figs. 6, 7).

**Table 1** Parameters recorded from urine and blood of groups of rats after 21 days of in vivo study

Parameters	Baseline	N. Saline	Ha.Cr 100	EG (0.75 %)	EG + Ha.Cr 30	EG + Ha.Cr 100
Change in BW		16.1 ± 1.4	18 ± 3.4	−3.3 ± 2.3**	8.33 ± 4.1 <sup>##</sup>	10.74 ± 2.8 <sup>##</sup>
Urine vol (ml/24 h)	6.5 ± 0.8	7.6 ± 1.2	12.4 ± 1.6	15 ± 1.5**	11.7 ± 1.7 <sup>#</sup>	8.5 ± 0.6 <sup>#</sup>
Urine vol (ml/24 h)	8.2 ± 0.7	8.5 ± 1.1	10.8 ± 1.3	14.4 ± 0.9**	12.4 ± 1.0 <sup>#</sup>	10 ± 0.6 <sup>#</sup>
pH	6.6 ± 0.08	6.5 ± 0.21	6.6 ± 0.06	6.4 ± 0.12	6.9 ± 0.2	6.6 ± 0.29
Urinary (mg/24 h)						
Oxalate	0.80 ± 0.20	0.72 ± 0.19	0.82 ± 0.10	2.34 ± 0.32*	1.39 ± 0.27	1.37 ± 0.15 <sup>#</sup>
Citrate	12.21 ± 2.1	13.59 ± 1.3	5.5 ± 0.71	4.47 ± 0.59	4.02 ± 0.54	4.39 ± 0.54
Phosphate	4.01 ± 0.71	4.41 ± 0.52	5.5 ± 0.71	4.47 ± 0.59	4.02 ± 0.54	4.39 ± 0.54
Uric acid	0.62 ± 0.06	0.7 ± 0.07	0.72 ± 0.06	0.63 ± 0.05	0.60 ± 0.08	0.61 ± 0.10
Calcium	4.06 ± 0.48	5.01 ± 0.52	5.75 ± 0.71	2.67* ± 0.41	3.15 ± 0.36	3.28 ± 0.34
Mg <sup>++</sup>	4.1 ± 0.68	5.05 ± 0.53	4.21 ± 0.53	5.11 ± 0.90	4.03 ± 0.61	4.38 ± 0.87
K <sup>+</sup>	0.76 ± 0.08	0.77 ± 0.07	0.71 ± 0.10	0.72 ± 0.06	0.78 ± 0.08	0.72 ± 0.09
Total protein	3.5 ± 1.00	4.6 ± 1.20	5.5 ± 0.70	12.4 ± 1.07**	7.48 ± 0.93 <sup>#</sup>	9.09 ± 0.57 <sup>#</sup>
Serum						
Creatinine (mg/dl)		0.73 ± 0.11	0.45 ± 0.06	1.4 ± 0.15**	0.81 ± 0.08*	0.81 ± 0.08 <sup>#</sup>
BUN (mg/ml)		22.9 ± 3.9	25.14 ± 3.9	40.19 ± 3*	26.28 ± 3.9	21.58 ± 3.47 <sup>#</sup>

Values are expressed as Mean ± SEM

\*  $p < 0.05$ , \*\*  $p < 0.05$  and \*\*\*  $p < 0.001$  versus normal

<sup>#</sup>  $p < 0.05$ , <sup>##</sup>  $p < 0.01$  and <sup>###</sup>  $p < 0.001$  versus lithogenic group


## Discussion

To investigate the medicinal use of *Holarrhena antidy-senterica* in urolithiasis, we evaluated crude extract for its antiurolithic activity using different in vitro assays and in vivo rat model of urolithiasis.

The effect of Ha.Cr on CaOx crystallization kinetics was studied by the time course measurement of turbidity using aggregometer, as already reported in previous studies [25, 35]. The initial positive slope of the turbidity curve, called the slope of nucleation ( $S_N$ ), is mainly due to an increase in the particle number resulting from crystal nucleation. After a plateau is achieved, a gradual decrease of absorbance (negative slope) despite continuous stirring reflects the decrease in the particle number, due to crystal aggregation [25, 35]. In this experiment, unlike potassium citrate, Ha.Cr had no effect on the slope of nucleation but inhibited the CaOx crystals aggregation in a concentration-dependent manner, similar to potassium citrate, a well-known inhibitor of CaOx crystallization and clinically used for the management of urolithiasis [36]. Similarly, in the incubation study, Ha.Cr caused a decrease in crystal size and transformed COM to COD crystals, which are less likely to attach with the kidney epithelial cells than COM crystals [38, 39] like that of citrate and Mg<sup>2+</sup> [37]. Crystal polymorphism plays an important role in calcium oxalates nephrolithiasis. COM crystals are thermodynamically more stable and more frequent in kidney stones as compared to

COD. Macromolecules isolated from urine of normal healthy individuals inhibit COM crystals and favors the formation of COD, which are less likely to adhere to renal epithelial cells. This suggests that COD formation protects against stone disease because of its reduced capacity to form stable aggregates and strong adhesion contacts to renal epithelial cells and thus potentially inhibiting a critical step in the formation of kidney stones [38, 39].

Calcification is a multifactorial phenomenon [40], developing as a result of a cascade of events initiated by supersaturation, including crystal nucleation, growth, aggregation and retention [41]. Various crystal inhibitors like potassium-sodium citrate and magnesium oxide have been shown to decrease the saturation of CaOx and inhibit crystal nucleation, growth and aggregation, while reduced crystallization in urine of stone forming patients [42]. Interference with crystal growth and aggregation, therefore, seems a possible therapeutic strategy for the prevention of recurrent stone disease. The effect on CaOx crystal aggregation might be due to the presence of saponins, present in the crude extract, which is evident from the phytochemical screening in our previous study [21], as saponins have been reported to have anti-crystallization property by disaggregating the suspension of mucoproteins, which are promoters of crystallization [43]. This shows that the Ha.Cr may contain substances that inhibit CaOx crystal aggregations and thus preventing a critical step in urinary stone formation, as larger particles are less



**Fig. 5** Images of crystalluria. Images of calcium oxalate crystals in 3 h morning urine collected from normal control (a), lithogenic control (b) and treated with *Holarrhena antidysenterica* (Ha.Cr) (c), under light microscope at 400 $\times$  magnification


likely to pass spontaneously in urinary tract. If the extract keeps CaOx particles dispersed in solution then they can be easily eliminated [44].

Animal and cellular studies have revealed that oxalate ions, or COM and hydroxy apatite (HA) crystals cause injury to the kidney cells [45, 46], most probably by the production of reactive oxygen species (ROS). Epithelial

injury is considered to be a risk factor for the crystallization and crystals deposition in the kidney, as it promotes crystal nucleation, aggregation, retention and stone development [45, 47]. Antioxidants, such as vitamin E, catechin and selenium, have been shown to provide protection against oxidative injury by oxalate and crystal deposition [48, 49]. When tested for its antioxidant activity, Ha.Cr caused scavenging of DPPH free radical and inhibited ferrous-ascorbate-induced lipid peroxidation of rat kidney homogenate similar to BHT, a standard antioxidant [50]. These results are in line with earlier study [51] which showed the presence of antioxidant activity in *Holarrhena antidysenterica*. As hyperoxaluria and COM crystals are known to cause oxidative stress resulting in toxicity of renal epithelial cells [49, 52], the protective effect of Ha.Cr on renal epithelial cell might be due to its antioxidant activity, as pretreatment with the Ha.Cr significantly increased the survival rate and reduced the LDH release, a marker of cell membrane damage, in MDCK cells, when exposed to oxalate and COM crystals.


For the in vivo antiurolithic effect of Ha.Cr, 0.75 % ethylene glycol (EG) and 1 % ammonium chloride (AC)-induced hyperoxaluric rat model of urolithiasis was used. Since the stone inducing treatment, Ethylene glycol (EG), was given orally, therefore, the extract was given i.p. to prevent any potential interaction of EG with plant constituents inside gut, interfering with absorption of either of the two. We have used intra-peritoneal (i.p) route, which is also commonly used in previous studies [11, 25, 53, 54].

Administration of EG and AC resulted in the increased CaOx crystalluria, with larger crystals due to hyperoxaluria, increase in water intake and urine output, which might be due to the renal impairment [29], as evident by increase in serum creatinine, BUN and total urinary protein loss in lithiatic group as compared to normal. Consistent with some previous reports, stone induction by hyperoxaluria caused an increase in oxalate and decrease in  $\text{Ca}^{2+}$  excretion in the untreated group [52, 55]. Hyperoxaluria is one of the major risk factor in the pathogenesis of kidney stone formation [56], as it causes oxidative stress and damages the renal epithelial cells thereby providing a nidus for crystals attachment and ultimately causes crystal aggregation retention and deposition in the kidney [45, 47]. Therefore, decrease in oxalate may explain its decrease in oxidative stress and renal crystal deposition. It is not uncommon that plant extracts may interfere with oxalate metabolism in animal model of urolithiasis, e.g. extract of *Aerva lanata* decreases the oxalate excretion, in ethylene glycol fed rats, by decreasing the formation of oxalate synthesizing enzymes like glycolic acid oxidase (GAO) in liver and lactate dehydrogenase (LDH) in liver and kidney [57]. Similar results were found in the extract of *Tribulus terrestris* [58]. This can be speculated that decrease in



**Fig. 6** Microscopic images of kidney sections in the in vivo study. Representative microscopic images of the H and E stain of the kidney sections from normal (**a**), lithogenic group (**b**) and treated (**c**) with

Ha.Cr. A1, B1 and C1 show the Pizzolato's staining of the respective kidney sections



**Fig. 7** CaOx crystal deposition score in preventive study. Calcium oxalate crystal deposition score after treatment with 0.75 % EG, 1 %  $\text{NH}_4\text{Cl}$  (lithogenic group); Ha.Cr 30 mg/kg and 100 mg/kg. Severity grade were assigned as 0 = <1 crystals, 1 = 1–10, 2 = 11–30, 3 = 31–50, 4 = 51–75 and 5 = >75 crystals; data are expressed as mean  $\pm$  SEM. \* $p$  < 0.05, \*\* $p$  < 0.05 and \*\*\* $p$  < 0.001

oxalate might be useful in hyperoxaluric kidney stone formers.

There was hypertrophy and extensive CaOx crystal deposition in kidneys of untreated rats. The renal tubules were markedly dilated, which might be due to the obstruction in distal renal tubular flow by large crystals [29]. Several in vivo and in vitro studies have demonstrated that hyperoxaluria, a major risk factor for calcium oxalate nephrolithiasis, results in greater production of superoxide and hydroxyl free radicals, leading to antioxidant imbalance, cell membrane rupture and cell death [49, 59] which leads to CaOx crystal adherence and retention in renal tubules [49, 60]. Thus, it can be speculated that the inhibitory effect of the plant extract on CaOx crystal deposition in renal tubules is possibly caused by its antioxidant activity. The plant is considered relatively safer, as it has been used in different herbal preparations and supplements, such as Kutaj (*Holarrhena antidysenterica*), a herbal supplement, is used in humans for ailment of diarrhea and urinary disorders, which has also undergone clinical trials for several studies, with no reported side effect, for ulcerative colitis and bleeding piles [61–63].

Thus, these data suggest that the preventive effect of *Holarrhena antidysenterica* in urolithiasis is mediated through multiple pathways including inhibition of the CaOx crystal aggregation, antioxidant and epithelial cell protective effects, which provide a step forward for designing further studies on *Holarrhena antidysenterica* to establish its safety and efficacy for clinical use.

**Acknowledgments** This study was supported by the Higher Education Commission (HEC) of Pakistan as (1) indigenous PhD and (2)

International Research Support Initiative Program (IRSIP) scholarships awarded to Aslam Khan.

## References

- Coe FL, Keck J, Norton ER (1977) The natural history of calcium urolithiasis. JAMA 238:1519–1523
- Bashir S, Gilani AH, Siddiqui AA, Pervez S, Khan SR, Sarfaraz NJ, Shah AJ (2010) Berberis vulgaris root bark extract prevents hyperoxaluria induced urolithiasis in rats. Phytother Res 24:1250–1255
- Hussain M, Rizvi SA, Askari H, Sultan G, Lal M, Ali B, Naqvi SA (2009) Management of stone disease: 17 years experience of a stone clinic in a developing country. J Pak Med Assoc 59:843–846
- Srisubut A, Potisat S, Lojanapiwat B, Setthawong V, Laopaiboon M (2009) Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones. Cochrane Database Syst Rev CD007044
- Qiang W, Ke Z (2004) Water for preventing urinary calculi. Cochrane Database Syst Rev CD004292
- Coe FL, Evan AP, Worcester EM, Lingeman JE (2010) Three pathways for human kidney stone formation. Urol Res 38:147–160
- Moe OW, Pearle MS, Sakhaee K (2011) Pharmacotherapy of urolithiasis: evidence from clinical trials. Kidney Int 79:385–392
- Hess B (2003) Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi. Ther Umsch 60:79–87
- Mattle D, Hess B (2005) Preventive treatment of nephrolithiasis with alkali citrate—a critical review. Urol Res 33:73–79
- Kmiecik J, Kucharska E, Sulowicz W, Ochmanski W (1997) Etiology and pathogenesis of urolithiasis. Przegl Lek 54:173–179
- Khan A, Bashir S, Khan SR, Gilani AH (2011) Antiuro lithic activity of Origanum vulgare is mediated through multiple pathways. BMC Complement Altern Med 11:96
- Gilani AH, Rahman AU (2005) Trends in ethnopharmacology. J Ethnopharmacol 100:43–49
- Butterweck V, Khan SR (2009) Herbal medicines in the management of urolithiasis: alternative or complementary? Planta Med 75:1095–1103
- Usmanghani K, Saeed A, Alam MT (1997) Indusynic medicine. University of Karachi Press, Karachi, pp 255–256
- Duke JA, Bogenschutz-Godwin MJ, Du celliar J, Duke PK (2002) Handbook of medicinal herbs, 2nd edn. CRC Press, Boca Raton, p 219
- Kapoor LD (1990) Hand book of ayurvedic medicinal plants. CRC Press, Boca Raton, pp 205–206
- Duke JA (1992) Hand book of phytochemical constituents of GRAS herbs and other economic plants. CRC Press, Inc., Boca Raton, pp 292–293
- Aqil F, Zahin M, Ahmad I (2008) Antimutagenic activity of methanolic extracts of four ayurvedic medicinal plants. Indian J Exp Biol 46:668–672
- Aqil F, Ahmad I (2007) Antibacterial properties of traditionally used Indian medicinal plants. Methods Find Exp Clin Pharmacol 29:79–92
- Atal CK, Sharma ML, Kaul A, Khajuria A (1986) Immunomodulating agents of plant origin. I: preliminary screening. J Ethnopharmacol 18:133–141
- Gilani AH, Khan A, Khan AU, Bashir S, Rehman NU, Mandukhail SU (2010) Pharmacological basis for the medicinal use of *Holarrhena antidysenterica* in gut motility disorders. Pharm Biol 48:1240–1246

22. Khan A, Bashir S, Gilani AH (2012) An in vivo study on the diuretic activity of *Holarrhena antidysenterica*. Afr J Pharm Pharmacol 6:454–458
23. National Research Council (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington, DC
24. Williamson EM, Okpako DT, Evans FJ (1996) Selection, preparation, and pharmacological evaluation of plant material. Wiley, Chichester
25. Bashir S, Gilani AH (2009) Antiuro lithic effect of *Bergenia ligulata* rhizome: an explanation of the underlying mechanisms. J Ethnopharmacol 122:106–116
26. Ajith TA, Usha S, Nivitha V (2007) Ascorbic acid and [alpha]-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta 375:82–86
27. Kang DG, Yun C, Lee HS (2003) Screening and comparison of antioxidant activity of solvent extracts of herbal medicines used in Korea. J Ethnopharmacol 87:231–236
28. Atmani F, Slimani Y, Mimouni M, Hacht B (2003) Prophylaxis of calcium oxalate stones by *Herniaria hirsuta* on experimentally induced nephrolithiasis in rats. BJU Int 92:137–140
29. Bashir S, Gilani AH (2011) Antiuro lithic effect of berberine is mediated through multiple pathways. Eur J Pharmacol 651:168–175
30. Bashir S, Gilani AH (2011) Antiuro lithic effect of berberine is mediated through multiple pathways. Eur J Pharmacol 651:168–175
31. Pizzolato P (1971) Mercurous nitrate as a histochemical reagent for calcium phosphate in bone and pathological calcification and for calcium oxalate. Histochem J 3:463–469
32. Vanachayangkul P, Chow N, Khan SR, Butterweck V (2010) Prevention of renal crystal deposition by an extract of *Ammi visnaga* L. and its constituents khellin and visnagin in hyperoxaluric rats. Urol Res 33:189–195
33. Daly JA, Ertingshausen G (1972) Direct method for determining inorganic phosphate in serum with the “CentrifChem”. Clin Chem 18:263–265
34. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
35. Hess B, Meinhardt U, Zipperle L, Giovanoli R, Jaeger P (1995) Simultaneous measurements of calcium oxalate crystal nucleation and aggregation: impact of various modifiers. Urol Res 23:231–238
36. Tiselius HG (2003) Epidemiology and medical management of stone disease. BJU Int 91:758–767
37. Guerra A, Meschi T, Allegri F, Prati B, Nouvenne A, Fiaccadori E, Borghi L (2006) Concentrated urine and diluted urine: the effects of citrate and magnesium on the crystallization of calcium oxalate induced in vitro by an oxalate load. Urol Res 34:359–364
38. Wesson JA, Ward MD (2006) Role of crystal surface adhesion in kidney stone disease. Curr Opin Nephrol Hypertens 15:386–393
39. Sheng X, Ward MD, Wesson JA (2005) Crystal surface adhesion explains the pathological activity of calcium oxalate hydrates in kidney stone formation. J Am Soc Nephrol 16:1904–1908
40. Wang AY (2009) Vascular and other tissue calcification in peritoneal dialysis patients. Perit Dial Int 29(Suppl 2):S9–S14
41. Khan SR (1997) Animal models of kidney stone formation: an analysis. World J Urol 15:236–243
42. Kato Y, Yamaguchi S, Yachiku S, Nakazono S, Hori J, Wada N, Hou K (2004) Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis. Urology 63:7–11 (discussion 11–12)
43. Gurocak S, Kupeli B (2006) Consumption of historical and current phytotherapeutic agents for urolithiasis: a critical review. J Urol 176:450–455
44. Atmani F, Khan SR (2000) Effects of an extract from *Herniaria hirsuta* on calcium oxalate crystallization in vitro. BJU Int 85:621–625
45. Aihara K, Byer KJ, Khan SR (2003) Calcium phosphate-induced renal epithelial injury and stone formation: involvement of reactive oxygen species. Kidney Int 64:1283–1291
46. Escobar C, Byer KJ, Khaskheli H, Khan SR (2008) Apatite induced renal epithelial injury: insight into the pathogenesis of kidney stones. J Urol 180:379–387
47. Byer K, Khan SR (2005) Citrate provides protection against oxalate and calcium oxalate crystal induced oxidative damage to renal epithelium. J Urol 173:640–646
48. Santhosh Kumar M, Selvam R (2003) Supplementation of vitamin E and selenium prevents hyperoxaluria in experimental urolithic rats. J Nutr Biochem 14:306–313
49. Thamilselvan S, Khan SR, Menon M (2003) Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants. Urol Res 31:3–9
50. Babich H (1982) Butylated hydroxytoluene (BHT): a review. Environ Res 29:1–29
51. Zahin M, Aqil F, Ahmad I (2009) The in vitro antioxidant activity and total phenolic content of four Indian medicinal plants International. J pharm pharm Sci 1:88–95
52. Park HK, Jeong BC, Sung MK, Park MY, Choi EY, Kim BS, Kim HH, Kim JI (2008) Reduction of oxidative stress in cultured renal tubular cells and preventive effects on renal stone formation by the bioflavonoid quercetin. J Urol 179:1620–1626
53. Muruganandan S, Srinivasan K, Gupta S, Gupta PK, Lal J (2005) Effect of mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic rats. J Ethnopharmacol 97:497–501
54. Michelacci YM, Boim MA, Bergamaschi CT, Rovigatti RM, Schor N (1992) Possible role for chondroitin sulfate in urolithiasis: in vivo studies in an experimental model. Clin Chim Acta 208:1–8
55. Fan J, Glass MA, Chandhoke PS (1999) Impact of ammonium chloride administration on a rat ethylene glycol urolithiasis model. Scanning Microsc 13:299–306
56. Tiselius HG (1996) Solution chemistry of supersaturation. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management. Lippincott-Raven, Philadelphia, pp 33–64
57. Soundararajan P, Mahesh R, Ramesh T, Begum VH (2006) Effect of *Aerva lanata* on calcium oxalate urolithiasis in rats. Indian J Exp Biol 44:981–986
58. Sangeeta D, Sidhu H, Thind SK, Nath R (1994) Effect of *Tribulus terrestris* on oxalate metabolism in rats. J Ethnopharmacol 44:61–66
59. Santhosh Kumar M, Selvam R (2003) Supplementation of vitamin E and selenium prevents hyperoxaluria in experimental urolithic rats. J Nutr Biochem 14:306–313
60. Wiessner JH, Hasegawa AT, Hung LY, Mandel GS, Mandel NS (2001) Mechanisms of calcium oxalate crystal attachment to injured renal collecting duct cells. Kidney Int 59:637–644
61. Patel MV, Patel KB, Gupta SN (2010) Effects of Ayurvedic treatment on forty-three patients of ulcerative colitis. Ayu 31:478–481
62. Pal A, Sharma PP, Mukherjee PK (2009) A Clinical Study of Kutaja (*Holarrhena Antidysenterica* Wall) on Shonitarsha. Hindu 5(33):33
63. Paranjpe P, Patki P, Joshi N (2000) Efficacy of an indigenous formulation in patients with bleeding piles: a preliminary clinical study. Fitoterapia 71:41–45